

Management Certification

The undersigned, on behalf of Sangamo Therapeutics, Inc. ("the Company"), certifies that the information provided herein is accurate and complete to the best of the Company's knowledge.

1. The Company is current in its disclosure obligations pursuant to the following reporting standard:

SEC Reporting Obligations

- The Company has a reporting obligation under Section 13 or 15(d) of the Exchange Act
- The Company has a reporting obligation under Regulation A (Tier 2)
- The Company has a reporting obligation under Regulation Crowdfunding (CF)
- Other (please describe)

Other Reporting Obligations

- The Company is a U.S. bank, bank holding company, or similar financial institution exempt from SEC registration, has a reporting obligation to a U.S. Bank Regulator and follows OTC Markets' Bank Reporting requirements.
- The Company is exempt from SEC registration and is reporting under the Alternative Reporting Standard

2. Indicate below whether the Company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: No:

3. Indicate below whether the Company is subject to Bankruptcy or reorganization proceedings.

Yes: No:

4. The Company has a Verified Company Profile on OTCMarkets.com.
5. The Company is duly organized and in good standing under the laws of the state or jurisdiction in which the Company is organized or does business.
6. The Company understands and acknowledges its obligations to report company-related actions pursuant to Exchange Act Rule 10b-17 and FINRA Rule 6490.
7. The Company understands and acknowledges its obligations to publicly disclose material information in a timely manner in accordance with applicable U.S. federal securities laws, including but not limited to Section 10(b) of the Exchange Act and Rule 10b-5 thereunder.
8. The Company's transfer agent and its address are listed below. If the Company acts as its own transfer agent, indicate that by listing the Company and its information in the fields provided.¹

Transfer Agent: Computershare
Address: 150 Royall Street, Canton, MA 02021

¹ OTCQX, OTCQB, and OTCID companies are required to retain a transfer agent that participates in the Transfer Agent Verified Shares Program. OTCID companies that act as their own transfer agent may submit data directly to OTC Markets.

9. The Company's most recent Annual Report was prepared by:

Below is a list all law firm(s) and attorney(s) (including internal counsel) that acted as the Company's primary legal counsel in preparing its most recent annual report or, if no attorney assisted in preparing the disclosure, the person(s) who prepared the disclosure and their relationship to the Company.

Cooley LLP – Courtney Tygesson

10. The Company's Officers, Directors and 5% Beneficial Owners are listed below:

The table below provides information regarding all officers and directors of the Company, or any person that performs a similar function, regardless of the number of shares they own. To the best of the Company's knowledge, it includes all individuals or entities beneficially owning 5% or more of any class of the issuer's equity securities. To identify holders of 5% or more, companies may obtain a recent copy of their shareholder list that includes Non-Objecting Beneficial Owners or "NOBOs." SEC Reporting companies may also research their beneficial ownership and insider transaction filings such as on Schedules 13G or 13D or on Forms 3, 4, and 5.

As of (latest practicable date): 4/6/26

Individual Name (First, Last) or Entity Name (Include names of control person(s) if a corporate entity)	Position/Company Affiliation (ex: CEO, ≥ 5% beneficial owner)	City and State (Include Country if outside U.S.)	Number of Shares Owned (List common, preferred, warrants and options separately)	Class of Shares Owned	Percentage of Class of Shares Owned (undiluted)
Nikunj Jain	Interim Chief Financial Officer & Principal Accounting Officer	Dublin, CA	199,917	Common	0.04%
Scott Willoughby	Chief Legal Officer & Corporate Secretary	San Francisco, CA	561,406	Common	0.13%
Gregory Davis	Head of Research & Technology	Richmond, CA	147,817	Common	0.04%
Alexander Macrae	CEO	San Francisco, CA	1,626,406	Common	0.40%
Nathalie Stringfellow	Chief Development Officer	Berkeley, CA	588,711	Common	0.14%
Kenneth Hillan	Director	Lagunitas, CA	74,600	Common	0.01%
Margaret Horn	Director	San Carlos, CA	57,650	Common	0.01%
Robert Carey	Director	Park City, UT	74,600	Common	0.01%
Courtney Beers	Director	Seattle, WA	57,650	Common	0.01%
Karen Smith	Director	Snowmass Village, CO	77,100	Common	0.02%
James Meyers	Director	New York, NY	74,600	Common	0.02%
John Markels	Director	Summit, NJ	71,384	Common	0.02%
Stewart Parker	Director	Chapel Hill, NC	87,600	Common	0.02%
Armistice Capital LLC (Steven Boyd)	> 5% beneficial owner	New York, NY	41,596,536	Common	10.00%

Yorkville Advisors (Mark Angelo)	> 5% beneficial owner	Mountainside, NJ	34,398,393	Common	8.30%
----------------------------------	-----------------------	------------------	------------	--------	-------

Any additional material details, including conversion terms of any class of the issuer's equity securities, are below:

11. The Company has Convertible Debt as detailed below:

The following is a complete list of the Company's Convertible Debt which includes all promissory notes, convertible notes, convertible debentures, or any other debt instruments convertible into a class of the issuer's equity securities. The table includes all issued or outstanding convertible debt at any time during the last complete fiscal year and any interim period between the last fiscal year end and the date of this Certification.

Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period.

Date of Note Issuance	Principal Amount at Issuance (\$)	Outstanding Balance (\$) (include accrued interest)	Maturity Date	Conversion Terms (e.g., pricing mechanism for determining conversion of instrument to shares)	# Shares Converted to Date	# of Potential Shares to be Issued Upon Conversion ²	Name of Noteholder (entities must have individual with voting / investment control disclosed).	Reason for Issuance (e.g., Loan, Services, etc.)

Total Outstanding Balance:

Total Shares:

Any additional material details, including footnotes to the table are below :

Signature:

Name of Interim Chief Financial Officer & Principal Accounting Officer: Nikunj Jain

Title: Interim Chief Financial Officer & Principal Accounting Officer

Date: 15-Apr-2026

Signature: Nikunj Jain
Electronically signed by: Nikunj Jain
Reason: I approve this document
Date: 15-Apr-2026 16:35:38 PDT

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

² The total number of shares that can be issued upon full conversion of the Outstanding Balance. The number should not factor any "blockers" or limitations on the percentage of outstanding shares that can be owned by the Noteholder at a particular time. For purposes of this calculation, please use the current market pricing (e.g. most recent closing price, bid, etc.) of the security if conversion is based on a variable market rate.






Sangamo Therapeutics Inc. Management Certification

Final Audit Report

2026-04-15

Created:	2026-04-15
By:	Frances Tan (ftan@sangamo.com)
Status:	Signed
Transaction ID:	CBJCHBCAABAkloCCkv0jesZYeOpEcNNIC_e5yg5loid
Documents:	Sangamo Therapeutics Inc. Management Certification.docx (3 pages)
Number of Documents:	1
Document page count:	3
Number of supporting files:	0
Supporting files page count:	0

"Sangamo Therapeutics Inc. Management Certification" History

-  Document created by Frances Tan (ftan@sangamo.com)
Documents: Sangamo Therapeutics Inc. Management Certification.docx
2026-04-15 - 11:25:17 PM GMT- IP address: 12.190.191.58
-  Document emailed to Nikunj Jain (NJain@sangamo.com) for signature
2026-04-15 - 11:26:01 PM GMT
-  Email viewed by Nikunj Jain (NJain@sangamo.com)
2026-04-15 - 11:35:12 PM GMT- IP address: 104.47.74.126
-  Document e-signed by Nikunj Jain (NJain@sangamo.com)
Documents: Sangamo Therapeutics Inc. Management Certification.docx
Signing reason: I approve this document
Signature Date: 2026-04-15 - 11:35:38 PM GMT - Time Source: server- IP address: 98.37.188.35
-  Agreement completed.
2026-04-15 - 11:35:38 PM GMT